Immuno-oncology (IO) therapy is a new (and old) way to treat cancer by activating your immune system in the hope that it will attack your tumour. Our sister site ‘10-for-IO’ is a central resource for patient organisations to access information [...]
Results from a phase 2 study of sonepcizumab were published in the journal Cancer this week and showed encouraging overall survival and a favourable safety profile, although the study did not reach its primary endpoint of 2-month progression-free survival (PFS). [...]
Dr. Laurence Albiges, Oncologist, head of the GU Tumor Board at the Gustave Roussy speaking during ESMO 2016 about how immunotherapy has had an impact on the field of renal cell carcinoma (RCC). Watch the video.
Dose escalation of tyrosine kinase inhibitors (TKIs) after disease progression in patients with metastatic renal cell carcinoma (mRCC) can lead to a decrease in tumour burden and extend duration of therapy, according to a study. Read more
The European Medicines Agency (EMA) has approved Cabozantinib as a second-line treatment option for patients with advanced renal cell carcinoma (RCC) who have previously been treated with vascular endothelial growth factor (VEGF)-targeted therapy. Read more.
Novel targeted and immunological therapies may help improve the outlook for patients with renal cell carcinoma (RCC), according to Dr Basma Greef, of the department of oncology at the Cambridge University Hospitals NHS Foundation Trust in the United Kingdom. She [...]